arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

KYNTRA BIO, INC.

KYNB
$7.20 ▼ -0.05 (-0.69%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
52 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bullish
auto_awesome

Analytical Summary

KYNTRA BIO, INC. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $29.1M
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC 46.1%
FCF / Share $-0.99
Trailing P/E 2.4x
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

52-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$-1.47M
↓ -139.4%
Net Income Profit after all expenses
$11.97M
↑ +178.8%
Operating Margin Operating profit as % of sales
-369.7%
↓ -62.5%
FCF / Share Free cash flow per share
$-0.99
↑ +71.3%
Long-Term Debt Long-term obligations
$75.00M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
3
Financial Health
68
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 52 quarters